-
EMA to review Sanofi’s Dupixent drug for asthma
pharmaceutical-technolog
April 09, 2018
The European Medicines Agency (EMA) has agreed to review an application submitted by Sanofi for the use of Dupixent (dupilumab) to treat inadequately controlled moderate-to-severe asthma.
-
EMA agrees to review Sanofi's filing for dual SGLT-1/2 inhibitor sotagliflozin in type 1 diabetes
firstwordpharma
March 30, 2018
Sanofi announced?Thursday?that the European Medicines Agency (EMA) has accepted to review its?marketing application?for the experimental oral drug sotagliflozin
-
Real world data back Sanofi’s Toujeo for type I diabetes
pharmatimes
March 21, 2018
Sanofi has unveiled real-world data from the UK showing the efficacy of its long-acting basal insulin analogue Toujeo in treating patients with type I diabetes.
-
Sanofi and Regeneron Slash Cost of New Cholesterol Drug Praluent
biospace
March 13, 2018
One of the reasons the new class of cholesterol-lowering medications, PCSK9 inhibitors, have had trouble gaining traction in the marketplace is because of cost
-
Sanofi in talks with Evotec to out-licence antibiotic research
pharmaphorum
March 12, 2018
Sanofi is in talks with the German biotech Evotec to out-license most of its infectious disease R&D, including novel antimicrobial research.
-
EvoTec to command vast Sanofi resources in infectious disease R&D partnership
pharmafile
March 09, 2018
Sanofi has announced it is to team up with biotech drug discovery specialist EvoTec to leverage a new open innovation platform in the research and development of new treatments for infectious diseases.
-
Evotec and Sanofi Collaborate on Infectious Disease R&D Initiative
biospace
March 09, 2018
Sanofi Pasteur?and Germany-based?Evotec AG?have teamed up to form?an infectious disease research and development program?in Lyon, France.
-
FDA to review Sanofi’s Dupixent in asthma
pharmaphorum
March 06, 2018
The FDA is to review Sanofi/Regeneron’s Dupixent as a treatment for asthma, a new use that could more than double its sales following its previous approval for eczema.
-
Sanofi files Dupixent for severe asthma
pharmatimes
March 05, 2018
US regulators have accepted for review Sanofi/Regeneron’s biologic Dupixent as an add-on maintenance treatment in certain adults and adolescents with moderate-to-severe asthma.
-
Sanofi and Regeneron Seek FDA Approval of Dupixent as Add-On Asthma Therapy
biospace
March 05, 2018
Asthma patients may soon have a new treatment option.
ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
Pharma Sources Insight July 2025
